Fresh from the biotech pipeline: too much, too fast?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35102293.
- Also identified by DOI 10.1038/s41587-022-01208-2 and PMC identifier 8802986.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
2021 witnessed regulators’ continued push to accelerate approvals and adjust to COVID-19, but has the pendulum swung too far in drug makers’ favor?
Medical subject headings
- Biotechnology
- Drug Approval
- Drug Industry